Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma
| Autor: | Noriyuki Sato, Mark I. Greene, Yoshihiko Hirohashi, Qiang Wang, Hideo Takasu, Yasuaki Tamura, Kenjiro Kamiguchi, Satoko Inoda, Tetsuhiro Tsuruma, Tadashi Hasegawa, Kunihiko Ishitani, Munehide Nakatsugawa, Takeshi Terui, Tosei Ohmura, Toshihiko Torigoe, Emiri Nakazawa, Hiroko Asanuma, Kenji Kiriyama, Kenji Harada, Koichi Hirata |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cancer Research
Immunology Estrogen receptor HLA-A24 Antigen Breast Neoplasms Cell Cycle Proteins Biology Breast cancer Antigen Antigens Neoplasm medicine Immunology and Allergy Humans Protein Interaction Domains and Motifs Cloning Molecular Pharmacology Centrosome HLA-A Antigens Gene Expression Profiling Cancer Immunotherapy Active Nuclear Proteins medicine.disease HCT116 Cells Microarray Analysis Immunohistochemistry Tumor antigen Peptide Fragments Protein Transport Drug Resistance Neoplasm Monoclonal Cancer research Female Breast disease Breast carcinoma K562 Cells Protein Binding T-Lymphocytes Cytotoxic |
| Zdroj: | Journal of immunotherapy (Hagerstown, Md. : 1997). 32(5) |
| ISSN: | 1537-4513 |
| Popis: | Identification of tumor-associated antigens may facilitate vaccination strategies to treat patients with malignant diseases. We have found that the centrosomal protein, Cep55/c10orf3 acts as a novel breast carcinoma-associated tumor-associated antigen. Cep55/c10orf3 mRNA was detectable in a wide variety of tumor cell lines. Expression was barely detectable in normal tissues except for testis and thymus. Moreover, Cep55/c10orf3 protein could be detected by a monoclonal anti-Cep55/c10orf3 antibody (# 11-55) in 69.8% of breast carcinoma, 25% of colorectal carcinoma, and 57.8% of lung carcinoma tissues. The expression of Cep55/c10orf3 protein did not show any relationship with the hormone receptors such as estrogen receptor and progesterone receptor or expression patterns of p185 HER2/neu. We designed 11 peptides which displayed a human leukocyte antigen-A24 binding motif. One Cep55/c10orf3-peptide, Cep55/c10orf3_193(10) (VYVKGLLAKI), induced cytotoxic T lymphocytes (CTLs) in 3 of 3 patients with Cep55/c10orf3 (# 11-55)-positive breast carcinoma. A Cep55/c10orf3_193(10)-specific CTL clone could also recognize Cep55/c10orf3 (+) displayed on human leukocyte antigen-A24 (+) cancer cell lines. These data indicate that Cep55/c10orf3 peptides were naturally presented by breast cancer cells and can cause CTL clonal expansion in vivo. Monoclonal antibody # 11-55 and the Cep55/c10orf3_193(10) peptides may be useful as part of a therapeutic strategy for hormonal therapy or anti-p185 HER2/neu monoclonal antibody therapy-resistant breast carcinoma patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|